LEXINGTON, Mass., March 2, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), announced today the closing of its previously announced public offering of common stock. Curis sold 25,090,908 shares of its common stock in the offering at a price to the public of $2.75 per share, including the exercise in full by the underwriters of their option to purchase an additional 3,272,727 shares of common stock at the public offering price. Curis received net proceeds of approximately $64.7 million, after deducting underwriting discounts and commissions and estimated offering expenses.
Cowen and Company, LLC and RBC Capital Markets acted as joint book-running managers. Robert W. Baird & Co. Incorporated and Roth Capital Partners, LLC acted as co-lead managers for the offering.
The offering was made by Curis pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission ("SEC"). A prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and can be accessed on the SEC's website located at www.sec.gov. Copies of the prospectus supplement and accompanying prospectus relating to this offering may be obtained from:
| Cowen and Company, LLC | RBC Capital Markets |
| c/o Broadridge Financial Solutions | 200 Vesey Street |
| 1155 Long Island Avenue | 8th Floor |
| Edgewood, NY 11717 | New York, NY 10281-8098 |
| Attn: Prospectus Department | Attention: Equity Syndicate |
| Phone: (631) 274-2806 | Phone: (877) 822-4089 |
| Fax: (631) 254-7140 | Email: equityprospectus@rbccm.com |
This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor shall there be any sale of these securities, in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
Curis, Inc.
Curis is a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers.
Forward-Looking Statements: Statements contained in this press release about Curis that are not purely historical may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. The words "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects", "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements involve known and unknown risks and uncertainties that may cause Curis' actual results, performance or achievements to be materially different than those expressed or implied by the forward-looking statements Curis makes.Among the important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are risks relating to, among other things, Curis' business, operations and financial condition, and the impact of general economic, industry or political conditions in the United States or internationally. These and other risks are described in the reports filed by Curis with the SEC, including under the caption "Risk Factors" included in Curis' annual report on Form 10-K for the year ended December 31, 2014 filed with the SEC on February 24, 2015, Curis' prospectus supplement filed with the SEC on February 25, 2015, and in other filings that Curis periodically makes with the SEC.
Any forward-looking statements contained in this press release speak only as of the date hereof. While Curis may elect to update these forward-looking statements at some point in the future, Curis expressly disclaims any obligation to update any forward-looking statements, except as required by law.
CONTACT: Mani Mohindru, Ph.D.
Vice President, Corporate Strategy and Investor Relations
Curis, Inc.
617-503-6605
mmohindru@curis.com
Michael P. Gray
Chief Financial and Chief Business Officer
Curis, Inc.
617-503-6632
mgray@curis.com